Featured Studies Results

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

https://www.facingourrisk.org/research-clinical-trials/study/356/treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies

Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)

Treatment
Treatment study for people with advanced or metastatic cancers

---

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

https://www.facingourrisk.org/research-clinical-trials/study/321/pfizer-clinical-trials-for-metastatic-prostate-cancer-are-now-enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

---

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for MMR-D or MSI-H Stage IIB - III Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/358/post-surgery-immunotherapy-toripalimab-for-mmr-d-msi-h-stage-iib-iii-colon-cancer

Clinicaltrials.gov identifier:
NCT07140679 (https://clinicaltrials.gov/show/NCT07140679)

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

---

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334/study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

---

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer

Clinicaltrials.gov identifier:
NCT05646316 (https://clinicaltrials.gov/show/NCT05646316)

Treatment
People with stage I endometrial cancer who are having a hysterectomy

---

The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/299/the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer

Clinicaltrials.gov identifier:
NCT05961709 (https://clinicaltrials.gov/show/NCT05961709)

Treatment
Treatment study for people with localized colon cancer who have dMMR

---

Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer

Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

---

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

---

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Clinicaltrials.gov identifier:
NCT03607890 (https://clinicaltrials.gov/show/NCT03607890)

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

---